- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04089631
Circulating Tumour DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation (CIRCULATE)
Circulating Tumour DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation (CIRCULATE) AIO-KRK-0217
Study Overview
Detailed Description
CIRCULATE is an investigator-initiated, multicentre, prospective, randomised, controlled trial.
Screening phase:
Patients with colon cancer (or rectal cancer, if a radiation is not indicated i.e. due to the tumour localisation) are postoperatively screened for this trial.
For this purpose, they sign an informed consent for screening. The formalin fixed paraffin embedded (FFPE) tumour block is shipped to one of the central pathological laboratories and is analysed for microsatellite instability and by panel analysis for frequent mutations in the colorectal cancer. A plasma sample is sent in parallel to the central laboratory for ctDNA. The screening is preferably performed before the patient is discharged from the surgical department and at the latest 5 weeks after resection to allow sufficient time for the analysis.
The patient- specific tumour mutations known from the panel analysis are measure in the patients plasma by ultra deep sequencing. The results of the analysis - positive for circulating tumour DNA (ctDNApos) or negative for circulating tumour DNA (ctDNAneg) - is not communicated to the patient or the investigator.
Randomised phase:
Four to eight weeks after resection, the patient presents at an investigator that is experienced with chemotherapy (i.e. Medical Oncologist) and consent for the randomised part of the study with a second informed consent form. If this baseline visit confirms that there are not contraindications to chemotherapy and if no other exclusion criteria exist, the patient is randomised:
- ctDNApos patients are randomised (2:1) in "chemotherapy" (with capecitabine) or "follow-up",
- ctDNAneg patients are randomised (1:4) in "follow-up" or "off study" which means that the follow-up will be organised within the routine clinical practice.
The result of the ctDNA will not be communicated to the patients and investigators, so that patients in the arm "follow-up" remain blinded to the ctDNA result. Due to the randomisation ratio, the prognosis of these patients is similar to those in stage II without any ctDNA analysis and differs only slightly from patients not enrolled into a clinical trial.
Patients in the arm "chemotherapy" receive adjuvant therapy with 6 months capecitabine. The investigator can decide to add oxaliplatin and to shorten the adjuvant chemotherapy to 3 months if oxaliplatin is added.
Patients in the arms "chemotherapy" and "follow-up" are followed with the same methods and time point within the study.
Patients in the arm "off study" are recommended to be follow up according to the guidelines for stage II in the routine practice.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Gunnar Folprecht, Prof.
- Phone Number: +49 351 458 4794
- Email: Gunnar.Folprecht@uniklinikum-dresden.de
Study Locations
-
-
Sachsen
-
Dresden, Sachsen, Germany, 01307
- Recruiting
- Universitaetsklinikum Carl Gustav Carus, Medizinische Klinik
-
Contact:
- Gunnar Folprecht, Dr.
- Phone Number: +49 351 458 4794
- Email: gunnar.folprecht@uniklinikum-dresden.de
-
Principal Investigator:
- Gunnar Folprecht, Dr.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria for screening phase:
- Resected colon cancer stage II, OR Resected rectal cancer stage II, if there was no indication for radiotherapy (i.e. due to the localisation in the upper third of the rectum ), so that the treatment follows the recommendations for colon cancer. Patients, in whom the tumour stage is not yet know, can be enrolled into the screening.
- Signed informed consent for the screening Phase
Inclusion criteria for the randomised phase:
- Resected colon cancer stage II, OR resected rectal cancer stage II, if there was no indication for radiotherapy (i.e. due to the localisation in the upper third of the rectum), so that the treatment follows the recommendations for colon cancer.
- Known microsatellite or mismatch repair status
- Confirmation, that the ctDNA result is available
- Signed second informed consent (for the randomised phase)
Exclusion criteria for Screening:
- Patients with known microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR)
- Known clinical high risk situation if it is regarded as certain indication for an adjuvant chemotherapy
- Patients, who have an obvious contra-indication for adjuvant chemotherapy (i.e. due to the performance status, comorbidity, active second cancer or age). It should be considered that patients with an age of more than 75 years frequently not fulfil criteria for adjuvant chemotherapy.
- R1- or R2-status (patients with [still] unknown R-status can be screened)
- Patients, in whom the randomisation or chemotherapy is unfeasible due to logistic reasons (travel distance, compliance)
- Age < 18 years
- Pregnant or breast feeding patients
Exclusion criteria for randomised phase:
- Patients with microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR)
- Known clinical high risk situation if it is regarded as certain indication for an adjuvant chemotherapy
- R1- or R2- status, or unknown R- status (Rx)
- Number of investigated lymph nodes < 10
- WHO performance status ≥ 2
- Colon or rectal cancer with UICC stage III or IV
Second cancer, except
- simultaneous or metachronous colon or rectal cancer with UICC stage ≤ I,
- curatively treated basal cell carcinoma or squamous cell carcinoma of the skin and in-situ cervical carcinoma
- tumours with a disease free survival of more than five years
Contra indications for chemotherapy, especially:
- Leukocytes < 3,0 Gpt/l
- Neutrophil granulocytes < 1,5 Gpt/l
- Thrombocytes < 100 Gpt/l
- alanine aminotransferase (ALAT) or (aspartate aminotransferase) ASAT > 3x ULN
- Creatinine clearance (calculated according Cockcroft-Gault) < 30 ml/min
Comorbidities relevantly interfering with the prognosis of the patients, i.e.:
- heart insufficiency NYHA III/IV
- relevant coronary heart disease,
- Diabetes mellitus with late sequelae
- Organ, stem cell or bone marrow transplantation
- Known hypersensitivity to capecitabine In case of known hypersensitivity to oxaliplatin, the patients can participate, but not receive oxaliplatin
- Medication with brivudine, sorivudine or analogues in the last four weeks before planned treatment start
- Known dihydropyrimidine dehydrogenase (DPD)-deficiency
- Acute infections
- Known HIV- infections, known active hepatitis B or C-infection
- Participation at another interventional study for medical treatment during the last four weeks before randomisation
- Neoadjuvant therapy before resection
- Patients, in whom the randomisation or chemotherapy is unfeasible due to logistic reasons (travel distance, compliance)
- Age < 18 years
- Pregnant or breast feeding patients
- Women of childbearing potential and men with partner with childbearing potential who are not willing to take appropriate precautions to avoid pregnancy with a highly effective method in case they are randomised to "chemotherapy"
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Chemotherapy
Capecitabine mono or Capecitabine/Oxaliplatin as investigator choice: Patients who are positive for postoperative ctDNA (ctDNApos) and not microsatellite instable are randomized (2:1) to adjuvant chemotherapy with capecitabine or to follow up. Capecitabine 2 x 1250 mg/m^2, oral (d1-14), repeated at day 22 (- 2 ... + 6 days). Patients with a GFR between 30 and 50 ml/min start with capecitabine dose of 2 x 1000 mg/m^2. Treatment duration: 8 cycles (approx. 6 months) Capecitabine, if combined with Oxaliplatin (investigator choice): If the investigation decides to add oxaliplatin, the following schedule should be used: [Oxaliplatin 130 mg/m^2 i.v. (2 hours on d1)] Capecitabine 2 x 1000 mg/m^2, oral (d1-14), repeated at day 22 (- 2 ... + 6 days) Treatment duration: 4 or 8 cycles (approx. 3 or 6 months) |
6 months capecitabine, in combination with oxaliplatin 3 to 6 months capecitabine
Other Names:
|
No Intervention: Follow-up
Patients negative for postoperative ctDNA (ctDNAneg) are randomized (1:4) to follow-up within CIRCULATE or to routine follow up outside the Trial protocol.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease free Survival (DFS)
Time Frame: for the primary endpoint after 154 events (approx. 60 months after study start)
|
Disease free survival of ctDNA positive patients randomised to "chemotherapy" vs. "follow-up", measured from randomisation to any recurrence, metastasis, second colorectal or non colorectal cancer and death from any cause. The primary endpoint will be tested in all randomised ctDNA positive patients and be evaluated by a stratified log rank test. Interims analysis after 93 events (approx. 38 months after study start), final analysis for the primary endpoint after 154 events (approx. 60 months after study start). |
for the primary endpoint after 154 events (approx. 60 months after study start)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival in ctDNApos patients with adjuvant therapy vs follow-up
Time Frame: 5 years
|
Overall survival in ctDNApos patients with adjuvant therapy vs follow-up, measured from randomisation to death from any cause, in all randomised ctDNA positive patients and be evaluated by a stratified log rank test.
|
5 years
|
Disease free survival in ctDNAneg patients randomised to follow up
Time Frame: 3 years
|
Disease free survival in ctDNAneg patients randomised to follow up (rate of patients disease free and alive 3 years after randomisation according to Kaplan-Meier estimation with 95% CI, intention-to-treat analysis).
Any recurrence, metastasis, second colorectal or non-colorectal cancer and death from any cause is regarded as event (rate of patients disease free and alive 3 years after randomisation according to Kaplan-Meier estimation with 95% CI, intention-to-treat analysis).
Any recurrence, metastasis, second colorectal or non- colorectal cancer and death from any cause is regarded as event
|
3 years
|
Overall survival in ctDNAneg patients randomised to "follow up"
Time Frame: 5 years
|
Overall survival in ctDNAneg patients randomised to "follow up" (rate of patients alive after 5 years after randomisation according to Kaplan-Meier estimation with 95% CI)
|
5 years
|
Disease free and overall survival of ctDNApos vs. ctDNAneg patients randomized to "follow-up"
Time Frame: 3 years and 5 years
|
Disease free and overall survival of ctDNApos vs. ctDNAneg patients randomized to "follow-up" (measured from randomisation to the event in an intention-to-treat analysis by stratified log rank test).
Any recurrence, metastasis, second colorectal or non-colorectal cancer and death from any cause are regarded as event for DFS.
Death of any cause will be regarded as event for overall survival.
|
3 years and 5 years
|
Site of metastases
Time Frame: 5 years
|
Site of metastases (lymph node vs. peritoneal/local recurrence vs other) in ctDNApos vs. ctDNAneg patients who have a recurrence / metastases
|
5 years
|
Frequency of adverse events from start of chemotherapy until 30 days after chemotherapy
Time Frame: 5 years
|
Frequency of adverse events from start of chemotherapy until 30 days after chemotherapy (descriptive analysis for patients randomised to "chemotherapy" who have received at least one dose of chemotherapy).
|
5 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Gunnar Folprecht, Prof., University hospital "Carl Gustav Carus" Dresden
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Colorectal Neoplasms
- Colonic Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Capecitabine
Other Study ID Numbers
- TUD-CIRC01-071
- 2018-003691-12 (EudraCT Number)
- 01KG1817 (Other Grant/Funding Number: German Federal Ministry for Education and Research (BMBF))
- AIO-KRK-0217 (Other Identifier: Arbeitsgemeinschaft Internistische Onkologie)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colon Cancer Stage II
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedStage I Colon Cancer | Stage I Rectal Cancer | Stage II Colon Cancer | Stage II Rectal Cancer | Stage III Colon Cancer | Stage III Rectal CancerUnited States
-
Baylor College of MedicineGenentech, Inc.Not yet recruitingStage I Colon Cancer | Stage II Colon Cancer | Stage III Colon CancerUnited States
-
National Cancer Institute (NCI)CompletedAdenocarcinoma of the Rectum | Stage I Colon Cancer | Stage I Rectal Cancer | Stage II Colon Cancer | Stage II Rectal Cancer | Stage III Colon Cancer | Stage III Rectal Cancer | Adenocarcinoma of the ColonUnited States
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)Active, not recruitingFinancial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing TreatmentStage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Colon Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Colon Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Stage IIA Rectal Cancer AJCC... and other conditionsUnited States
-
Gruppo Oncologico del Nord-OvestSeagen Inc.; Servier; Foundation MedicineRecruitingStage II Colon Cancer | Stage III Colon Cancer | HER2-positive Colon Cancer | RAS Wild-type Colon CancerItaly
-
University of Roma La SapienzaAssociazione Italiana per la Ricerca sul CancroRecruitingColon Cancer Stage II | Colon Cancer Stage IIIItaly
-
Sohag UniversityActive, not recruitingColon Cancer Stage II | Colon Cancer Stage IEgypt
-
Mayo ClinicNational Cancer Institute (NCI)CompletedCancer Survivor | Stage I Breast Cancer AJCC v7 | Stage IA Breast Cancer AJCC v7 | Stage IB Breast Cancer AJCC v7 | Stage II Breast Cancer AJCC v6 and v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedStage II Colon Cancer | Stage III Colon CancerUnited States
-
Sun Yat-sen UniversityRecruitingColon Cancer Stage II | Colon Cancer Stage IIIChina
Clinical Trials on Capecitabine
-
Sun Yat-sen UniversityChengdu Biostar PharmaceuticalsNot yet recruitingBreast Neoplasms | Locally Advanced or Metastatic Breast CancerChina
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruiting
-
Hoffmann-La RocheCompletedBreast Cancer, Colorectal CancerNew Zealand, Australia, United Kingdom
-
Samsung Medical CenterCompletedAdvanced or Recurrent Esophageal Squamous Cell CarcinomaKorea, Republic of
-
Fudan UniversityCompletedMetastatic Breast CancerChina
-
Binghe XuHoffmann-La RocheUnknownSkin Diseases | Neoplasms by Site | Breast Neoplasms | Breast Diseases | Neoplasm MetastasisChina
-
Jules Bordet InstituteCompletedBreast Cancer | Elderly PatientsBelgium
-
Cancer Institute and Hospital, Chinese Academy...Hoffmann-La RocheUnknownCarcinoma, Invasive Ductal, BreastChina
-
The First Affiliated Hospital of Zhengzhou UniversityRecruiting
-
Jiangxi Provincial Cancer HospitalNot yet recruitingNasopharyngeal Carcinoma | Maintenance Therapy | High-Risk Cancer